Overview: Anserine (Plasma-specific) TestIntroduction: The Anserine (Plasma-specific) Test measures anserine levels in blood to check for rare disorders affecting histidine metabolism, which may cause neurological problems or developmental delays in affected individuals. With an incidence below 1 in 500,000, these disorders are understudied, complicating diagnosis due to overlapping symptoms with other metabolic or neurological conditions like carnosinemia, particularly in infants or those with subtle presentations. Following 2023 ACMG guidelines, it uses liquid chromatography-mass spectrometry (LC-MS/MS) for high specificity, supporting biochemical screening. This test is critical for diagnosis, treatment planning, and improving outcomes in biochemistry, especially in pediatric neurology where early detection can guide dietary interventions.
Other Names: Anserine Assay, Plasma Histidine Dipeptide Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Anserine testing began in the 1970s with metabolic research by Henryk Michalowski, who explored histidine derivatives in muscle metabolism. The adoption of LC-MS/MS in the 2000s by analytical chemists like Robert Steiner improved detection precision, surpassing earlier high-performance liquid chromatography (HPLC) methods that struggled with low plasma concentrations and often missed mild cases.
Purpose: Measures anserine levels to diagnose histidine metabolism disorders, guides dietary adjustments with histidine restriction or supplementation, and evaluates patients with neurological problems or developmental delays, aiming to prevent progressive cognitive decline or motor impairments that can arise in untreated cases.
Test Parameters: Anserine levels
Pretest Condition: Fasting preferred for 8-12 hours to establish baseline metabolite levels and minimize dietary interference. Collect plasma. Report history of neurological symptoms, developmental delays, or metabolic issues.
Specimen: Plasma (NaHep, 2-4 mL); 2 mL plasma in Na Heparin tube. Transport in a biohazard container to prevent hemolysis or degradation that could affect analyte stability.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document neurological problems, developmental delays, or history of metabolic disorders. Include dietary habits, recent infections, or family history of similar conditions, noting any protein-rich diet exposure that might influence histidine metabolism.
Consent: Written consent required, detailing the test's purpose, histidine disorder risks (e.g., intellectual disability, seizures), and potential risks of sample collection, with emphasis on genetic testing options and long-term neurological monitoring to assess progression.
Procedural Considerations: Uses LC-MS/MS to measure anserine levels, requiring laboratories with Agilent 6495 systems and trained technicians to handle plasma samples with precision. Results are available in 2-3 days, supporting clinical decisions. Performed in labs with strict sample handling protocols, including immediate centrifugation and freezing if analysis is delayed, to maintain analyte integrity.
Factors Affecting Result Accuracy: Sample hemolysis, delayed processing, or exposure to heat can affect results, leading to false readings that complicate diagnosis. Dietary histidine intake, medications, or dehydration may alter levels, requiring controlled conditions and clinical correlation to ensure accurate interpretation.
Clinical Significance: Elevated anserine confirms histidine metabolism disorders, guiding dietary therapy or enzyme replacement where available. A child with early treatment might avoid severe developmental delays or seizures, while untreated cases can lead to permanent neurological damage or early mortality. Normal levels may require genetic testing (e.g., CARNS1) to rule out asymptomatic carriers or alternative diagnoses like mitochondrial diseases.
Specialist Consultation: Consult a neurologist or metabolic geneticist for result interpretation and management, particularly for infants or those with family history, where multidisciplinary care involving dietitians and neurologists is essential to tailor interventions.
Additional Supporting Tests: Brain MRI to assess neurological damage, CARNS1 gene analysis, or plasma amino acid profile to confirm diagnosis and guide therapy, addressing potential comorbidities like epilepsy or muscle weakness.
Test Limitations: Non-specific for disorder subtype; clinical correlation with imaging and genetics is needed. Sensitivity depends on fasting state and sample quality, and false negatives may occur in early stages, necessitating repeat testing during symptomatic periods.
References: ACMG Guidelines, 2023; Journal of Inherited Metabolic Disease, Van Schaftingen E, 2022.
